Haemozoin: from melatonin pigment to drug target, diagnostic tool, and immune modulator

Department of Chemistry, University of Cape Town, Kaapstad, Western Cape, South Africa
The Lancet Infectious Diseases (Impact Factor: 19.45). 11/2007; 7(10):675-85. DOI: 10.1016/S1473-3099(07)70238-4
Source: PubMed

ABSTRACT Plasmodium spp produce a pigment (haemozoin) to detoxify the free haem that is generated by haemoglobin degradation. Haemozoin was originally thought to be an inert waste byproduct of the parasite. However, recent research has led to the recognition that haemozoin is possibly of great importance in various aspects of malaria. Haemozoin is the target of many antimalarial drugs, and the unravelling of the exact modes of action may allow the design of novel antimalarial compounds. The detection of haemozoin in erythrocytes or leucocytes facilitates the diagnosis of malaria. The number of haemozoin-containing monocytes and granulocytes has been shown to correlate well with disease severity and may hold the potential for becoming a novel, automated laboratory marker in the assessment of patients. Finally, haemozoin has a substantial effect on the immune system. Further research is needed to clarify these aspects, many of which are important in clinical practice.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Malaria is an ancient disease continuing to pose an enormous health, social, and economic burden. It is caused by infection with protozoan parasites belonging to the genus Plasmodium transmitted via the bite of female Anopheles species mosquitoes. Of more than 100 different species infecting a wide range of animals from rodents and birds to mammals, five species of malaria parasites are known to infect humans: Plasmodium falciparum, P. vivax, P. ovale (now being recognized as consisting of two subspecies), P. malariae and P. knowlesi. P. falciparum is most likely to cause severe disease and, if not promptly treated, may lead to death. References to the disease occur in the Chinese canon of medicine, clay tablets from Mesopotamia, Egyptian papyri and Indian medical works. Descriptions of malaria from classic Greece and the Roman Empire are abundant. It was commonly believed that malaria was caused by marsh water and foul vapors emanating from swamps, hence the word mal’aria, from the Italian for “bad air”. For thousands of years, no effective treatment was available. This changed with the discovery of Artemisia annua (sweet wormwood) in China and the use of quinine from Peruvian bark as potent and effective drugs against malaria. The current understanding of the malaria parasites and their lifecycle starts in the end of the nineteenth century with the discovery of the malaria parasites in the blood of malaria patients by Alphonse Laveran in 1880. Subsequently, Ronald Ross discovered in 1897 that a bird malaria parasite was transmitted by mosquitoes. In 1898 Giovanni Grassi, Camillo Golgi, Ettore Marchiafava, Amico Bignami, Angelo Celli and Giuseppe Bastianelli confirmed that malaria in humans was also a mosquito-borne disease, in this case Anopheles species. Grassi and Filetti introduced the names of P. vivax and P. malariae in 1890. The causative agent of what was dubbed ‘malignant malaria’ was baptized P. falciparum by William Welch in 1897 and P. ovale by John Stephens in 1922. The discovery of a liver stage before malaria enters the bloodstream was made by Henry Shortt and Cyril Garnham in 1948. The existence of dormant stages, in P. vivax and P. ovale was shown in 1982 by Wojciech Krotoski. This article describes the key discoveries and provides a short overview of the multifaceted history of malaria.
    Discoveries in Modern Science: Exploration, Invention, Technology, 1st Edition edited by James Trefil, Patricia Daniels, Donna McPhie, Craig Schiffries, 10/2014: chapter Malaria Is Transmitted by Mosquitoes: pages 640-647; Macmillan Reference USA., ISBN: 0028662482
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Children with recent or acute malaria episodes are at increased risk of invasive bacterial infections (IBI). However, the exact nature of the malaria-IBI association is still unclear. Young children have an age-related spleen immunologic immaturity, mainly due to the still ongoing development of the marginal zone (MZ) B cell subset. By mounting a rapid antibody response against encapsulated bacteria, these cells are critical for the defence against highly pathogenic microorganisms that do not elicit classical T cell-dependent responses. There is increasing evidence that the anatomy of the spleen becomes disorganized during malaria infection, with complete dissolution of the MZ and apoptosis of MZ B cells. Correspondingly, a reduction in the frequency of the peripheral equivalent of the MZ B cells has been found in malaria endemic areas. A remarkable similarity exists in IBI susceptibility between African children with malaria and hyposplenic or splenectomized patients. However, studies specifically assessing the immune function of the spleen in controlling bacterial infections in young children with malaria are scarce.Here, it is hypothesized that Plasmodium falciparum malaria infection constitutes a detrimental factor in the still immature spleen function of young children, resulting in a factually hyposplenic state during malaria episodes, putting children with malaria at a high risk to develop life-threatening bacterial infections. Studies to confirm or reject this hypothesis are greatly needed, as well as the development of affordable and feasible tools to assess the immune spleen function against encapsulated bacteria in children with malaria.
    Malaria Journal 08/2014; 13(1):335. DOI:10.1186/1475-2875-13-335 · 3.49 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Serum lipid profile changes have been observed during malaria infection. The underlying biological mechanisms remain unclear. The aim of this paper is to provide an overview on those serum lipid profile changes, and to discuss possible underlying biological mechanisms and the role of lipids in malaria pathogenesis. A systematic review and meta-analysis to determine lipid profile changes during malaria was conducted, following PRISMA guidelines. Without language restrictions, Medline/PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, LILACS, Biosis Previews and the African Index Medicus were searched for studies published up to 11 July, 2013, that measured serum lipid parameters in malaria patients. Also, major trial registries were searched. Mean differences in lipid profile parameters were combined in fixed and random effects meta-analysis, with a separate analysis for different groups of controls (healthy, other febrile illnesses or very low parasitaemia). These parameters were also compared between severe malaria and uncomplicated malaria. Funnel plots were used to test for publication bias. Of 2,518 studies reviewed, 42 met the criteria for inclusion in the qualitative analysis, and of these, 15 reported the necessary data for inclusion in the meta-analysis for cholesterol; nine for high-density lipoprotein (HDL), eight for low-density lipoprotein (LDL), and nine for triglycerides, respectively. Total cholesterol, HDL and LDL concentrations were lower in malaria and other febrile diseases compared to healthy controls. The decline was more pronounced and statistically significant during malaria compared to other febrile diseases. These results were consistent across included studies. Triglycerides were raised compared to healthy controls, but not statistically significant when compared to symptomatic controls. This meta-analysis suggests that the observed lipid profile changes are characteristic for malaria. Although a definite link with the pathogenesis of malaria cannot yet be demonstrated, plausible hypotheses of biological mechanisms involving host lipid alterations and the pathogenesis of malaria exist. An increased research effort to elucidate the precise pathways is warranted, since this could lead to better understanding of malaria pathophysiology and consequently to novel treatment approaches.
    Malaria Journal 12/2013; 12(1):442. DOI:10.1186/1475-2875-12-442 · 3.49 Impact Factor